Abstract
Histopathologic evaluation plays an integral role in the overall assessment of the liver transplant. Pathologists are often asked to evaluate donor liver biopsies to assist in the determination of whether a marginal donor liver is suitable for transplantation. In addition, histopathologic assessment of allograft liver biopsies plays an important role in identifying the cause of allograft dysfunction and therefore in initiation of the appropriate therapeutic intervention. A detailed histopathologic evaluation is mandated, including histologic comparison with any previous biopsies as well as incorporation of all pertinent clinical, laboratory, and imaging findings with histologic assessment.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
Histopathologic evaluation plays an integral role in the overall assessment of the liver transplant. Pathologists are often asked to evaluate donor liver biopsies to assist in the determination of whether a marginal donor liver is suitable for transplantation. In addition, histopathologic assessment of allograft liver biopsies plays an important role in identifying the cause of allograft dysfunction and therefore in initiation of the appropriate therapeutic intervention. A detailed histopathologic evaluation is mandated, including histologic comparison with any previous biopsies as well as incorporation of all pertinent clinical, laboratory, and imaging findings with histologic assessment.
5.1 Evaluation of Donor Biopsies
Donor biopsies are often evaluated to determine the extent of steatosis. There are two different forms of steatosis—macrovesicular and microvesicular—with the macrovesicular form divided into large droplet and small droplet. Large droplet macrovesicular steatosis is generally defined as one large fat vacuole that occupies more than half of the cell and displaces the nucleus to the cell periphery (Fig. 5.1). In comparison, small droplet macrovesicular steatosis is defined as fat vacuoles that are smaller than half of the cell and do not displace the nucleus (Fig. 5.2). The term microvesicular steatosis is used when innumerable tiny lipid vesicles are diffusely distributed throughout the cytoplasm, giving it a foamy appearance [1–3]. The extent of steatosis is estimated as the percentage of liver parenchyma that is replaced by steatosis (Fig. 5.3). It is typically the extent of large droplet macrovesicular steatosis that is clinically significant because more or less than 30 % of this type of steatosis has been shown to be an independent risk factor for reduced short-term graft survival. The exact amount of steatosis that precludes an organ for transplantation is rather center-dependent and depends on various donor and recipient factors. Small droplet macrovesicular steatosis and microvesicular steatosis do not predictably result in graft dysfunction, and in many centers such as ours they are not used to determine graft usage. In our practice, we estimate the amount of fat in routine hematoxylin and eosin (H&E) staining (either requested as frozen section or rush permanent evaluation), and we do not perform any special fat stains. It is important that the biopsy specimen is freshly obtained and that frozen sections are evaluated immediately or the biopsy is placed in formalin for fixation, since exposure to air or saline can significantly alter the morphology and hamper the evaluation of the biopsy.
5.2 Allograft Rejection
Acute cellular rejection (ACR) is the most common type of rejection and the most common complication in the early post-transplant period. The diagnosis is based on three main histopathologic features: (1) mixed but predominantly mononuclear portal inflammation containing activated lymphocytes, neutrophils, and eosinophils; (2) subendothelial inflammation of portal and/or central veins (i.e., endotheliitis); and (3) bile duct inflammation and damage (Figs. 5.4, 5.5, and 5.6). The minimum diagnostic criteria for ACR are generally accepted as the presence of at least two of these features [4]. However, because these findings may vary considerably in different areas of the graft, it is recommended that a minimum of five portal tracts and at least two sections at different levels be examined when evaluating allograft biopsies [5].
Once the diagnosis of acute rejection has been established based on the above criteria, the Banff schema (Table 5.1) is applied to grade the severity of acute rejection [6]. The schema assesses the severity of inflammation, combined with morphologic evidence of rejection-related ischemia, which is the final mechanism of allograft failure in ACR. A descriptive grading of rejection is rendered based on an overall evaluation of the parameters listed in Table 5.1. In general, mild and moderate acute rejections are distinguished based on the extent of the portal inflammation, whereas the presence of perivenular inflammation and associated hepatocellular necrosis is used to distinguish severe acute rejection from the lower grades (Fig. 5.7). In most mild cases of ACR, the inflammatory infiltrate is limited to the portal tracts. The presence of prominent interface hepatitis indicates either a more severe form of ACR, a late form of ACR (see later description), or another concomitant cause of hepatitis. If more than one inflammatory condition is affecting the allograft (e.g., acute rejection and viral hepatitis), it is extremely difficult if not impossible to determine the relative contribution of each injury to the severity of the changes.
5.2.1 Late Acute Rejection
This form of rejection refers to a type of cellular rejection that occurs several months after transplantation and may show different histologic features as compared with typical ACR described earlier. Alternative names include centrizonal/parenchymal rejection, hepatitic variant of rejection, or atypical rejection. It is characterized by a hepatitic pattern of liver injury and can mimic hepatitis closely [7, 8]. Perivenular inflammation (central perivenulitis) is commonly seen, which may or may not be associated with centrilobular hepatocyte injury and necrosis (Fig. 5.8). Late acute rejection is considered a diagnosis of exclusion, and complete serologic studies (including rare forms of viral hepatitis such as hepatitis E) must be performed to rule out other etiologies of hepatitis. Of note, hepatitis E is an uncommon but increasingly recognized cause of acute and chronic hepatitis in the developed countries and should be considered in any post–liver transplant patient with a hepatitic pattern of injury. In general however, if central perivenulitis is present in less than 50 % of the lobules, the diagnosis of late acute rejection is favored [9].
5.2.2 Plasma Cell Hepatitis (PCH)
PCH is an immune-mediated post-transplant histologic pattern of injury. It is characterized by the presence of plasma cell–rich portal and lobular inflammatory infiltrates, including central perivenulitis, which closely resembles autoimmune hepatitis in the native liver (Fig. 5.9) [10]. While the pathophysiology is somewhat unclear, PCH is generally considered a form of rejection and is a negative prognostic factor for graft and patient outcomes. Patients with this pattern of injury are more likely to be resistant to increased immunosuppression and have an increased risk of fibrosis and graft loss [11–13].
5.2.3 Chronic Rejection (CR)
In comparison to other solid organ transplants (such as heart, lung, and kidney) in which CR may affect 30–50 % of allograft recipients, CR affects only 3–5 % of liver transplant recipients. Although late CR is considered an irreversible, progressive disease that leads to graft loss, early CR is considered potentially reversible [14]. Early CR is identified by degenerative changes of the biliary epithelium, even before duct loss. These include uneven spacing of biliary epithelial cells, loss of nuclear polarity, and increased cytoplasmic eosinophilia (Fig. 5.10). Late CR is characterized by bile duct loss involving greater than 50 % of portal tracts (Fig. 5.11). Other lobular features that may be seen in later phases of CR include clusters of pigmented foamy macrophages, canalicular cholestasis, pericentral hepatocyte atrophy, and/or ballooning and perivenular fibrosis (Figs. 5.12, 5.13, and 5.14). While foam cell obliterative arteriopathy is the characteristic feature of CR, this finding is only rarely seen in needle core biopsies (Fig. 5.15). The minimum diagnostic criteria for histopathologic diagnosis of CR are defined as follows [15]: (1) the presence of bile duct atrophy/senescence affecting most of the bile ducts, with or without bile duct loss (early CR), (2) foam cell obliterative arteriopathy (OA) with accumulation of foamy, lipid-laden histiocytes within the myointimal layer, or (3) loss of interlobular bile ducts in at least 50 % of the portal tracts (late CR).
5.2.4 Antibody-Mediated Rejection (AMR)
AMR is becoming increasingly recognized in liver allografts. However, it remains a controversial area because its diagnostic criteria and histologic features have not been fully established. In general, AMR may be considered if other etiologies of allograft dysfunction have been excluded and if donor-specific antibodies (DSAs) are discovered in the patient’s serum. Histologic features that have been reported include portal edema and neutrophilic inflammation with ductular reaction (i.e., features similar to those of bile duct obstruction), hepatocellular necrosis (i.e., features of ischemic injury) as well as portal vein endothelial cell hypertrophy, portal eosinophilia, and eosinophilic central venulitis (Fig. 5.16). Diffuse C4d deposition in the portal vein and sinusoids, demonstrated by immunohistochemistry and/or immunofluorescence, has been described in cases with clinical suspicion of AMR in the presence of DSAs (Fig. 5.17) [16–18]. However, the C4d stain remains a nonspecific stain, and its clinical utility remains unclear because positivity has also been reported in cases of ACR, CR, recurrent hepatitis B and C, biliary obstruction, vascular thrombosis, and even normal allograft livers [19]. The Banff schema consensus guidelines for diagnosis of AMR and C4d interpretation in liver allograft are expected to be released in the near future.
5.3 Recurrent Disease
Recurrent disease is a major cause of graft dysfunction. Examples of some of the more common recurrent diseases follow.
5.3.1 Recurrent Hepatitis C
Recurrent hepatitis C is a major differential diagnosis of ACR, including late acute rejection. Early recurrence is characterized by a predominance of lobular activity with frequent apoptotic bodies (Figs. 5.18 and 5.19). Later there is a transition to predominantly portal infiltrates and interface hepatitis typical of chronic hepatitis C in native livers. The histologic feature that is very useful in determining whether acute rejection is present in the setting of recurrent hepatitis C is endotheliitis. However, it may not be present in late acute rejection. Table 5.2 contains histologic features helpful in differentiating ACR from recurrent hepatitis C.
5.3.2 Fibrosing Cholestatic Hepatitis (FCH)
This is a rare and aggressive form of viral hepatitis infection that occurs in patients with severe immunosuppression. It has been described in patients with both hepatitis B and C. Histologically, FCH is characterized by marked hepatocellular injury in the form of lobular disarray and ballooning changes in addition to prominent intracellular and canalicular cholestasis, ductular reaction, and periportal and pericellular/sinusoidal fibrosis (Fig. 5.20) [20–23]. There is generally a paucity of portal and lobular inflammatory infiltrate. This is a diagnosis of exclusion and requires clinicopathologic correlation with a markedly elevated viral load and exclusion of bile duct obstruction by imaging studies.
5.3.3 Primary Biliary Cirrhosis (PBC)
The histopathologic findings of recurrent PBC are identical to those seen in native livers. Given the presence of bile duct injury and/or loss in cases of recurrent PBC (Fig. 5.21), the differential diagnosis between acute and chronic rejection can be challenging. (See Tables 5.1 and 5.2 for histologic features that are helpful in this distinction.)
5.3.4 Primary Sclerosing Cholangitis (PSC)
Recurrent PSC cannot be reliably distinguished from other forms of biliary obstruction on biopsy specimens, and cholangiography is essential in establishing a diagnosis. In addition, distinguishing PSC from chronic rejection can be challenging because both PSC and chronic rejection may result in atrophy and loss of interlobular bile ducts. However, features of PSC that are not typically seen in chronic rejection include portal inflammation, ductular reaction, and portal fibrosis (see Table 5.3).
5.4 Infections
5.4.1 Cytomegalovirus Hepatitis (CMV)
CMV can infect hepatocytes, endothelial cells, and bile duct epithelial cells. Infected cells have an enlarged nucleus with an eosinophilic inclusion surrounded by a clear halo [24]. The cytoplasm often also contains eosinophilic granular inclusions. Adjacent liver sections may show clusters of neutrophils forming characteristic neutrophilic “microabscesses” (Figs. 5.22 and 5.23). In fact, this finding in isolation is considered a reasonable indication for performing immunohistochemical analysis to evaluate for CMV.
5.4.2 Adenovirus Hepatitis
Adenoviral infection is characterized by patchy nonzonal coagulative necrosis. Typically, hepatocytes peripheral to the necrosis demonstrate smudgy nuclei with chromatin margination (Fig. 5.24).
5.4.3 Herpes Simplex (HSV) and Varicella-Zoster (VZV) Hepatitis
HSV and VZV infections occur secondary to reactivation from latency any time post-transplant. These infections are similar histologically and show variable degrees of hepatocellular necrosis (up to massive) with the typical nuclear features of herpes infection, including multinucleation with molding of nuclei, margination of chromatin, and glassy nuclear inclusions (Fig. 5.25).
5.4.4 Epstein Bar Virus (EBV) Hepatitis
EBV infection is also seen as a reactivation from a previous infection. It might present as a range of histologic changes from mild EBV hepatitis seen as portal and sinusoidal lymphocytic infiltrate to post-transplant lymphoproliferative disorder (PTLD) (see later description). In situ hybridization testing for EBV-encoded RNA (EBER) is helpful.
5.5 Other Complications
5.5.1 Preservation/Reperfusion Injury
This is one of the most common causes of allograft dysfunction within the first several weeks after transplantation. It is a general term that refers to the injury that may happen at any time, starting from the donor organ’s acquisition, harvesting, and implantation into the recipient. It includes the cold ischemic time of the donor organ as well as injury related to postperfusion. Histologically, it is typically seen as pericentral sinusoidal congestion with neutrophilic infiltration of lobules accompanied by necrotic/apoptotic hepatocytes (Fig. 5.26).
5.5.2 Vascular Thrombosis
This is one of the most serious post-transplant technical complications and most often involves the hepatic artery. It most frequently occurs during the first several weeks post-transplant and less frequently 1–3 years after transplantation. Vascular compromise may be seen as pericentral hepatocellular damage, manifested as hepatocellular ballooning with cholate stasis and cholestasis (Fig. 5.27). In more severe cases, pericentral hepatocellular necrosis is present (Fig. 5.28). Other causes of pericentral necrosis in liver allografts include ischemic shock from hypovolemia or sepsis. Patients with sepsis or intra-abdominal infection have a characteristic pattern of injury, so-called subacute nonsuppurative cholangitis, also known as cholangitis lenta (Fig. 5.29) [25, 26].
5.5.3 Biliary Strictures/Bile Duct Obstruction
Biliary tract complications are a common source of dysfunction in the liver allograft. Histologic features include portal expansion with edema (neutrophilic), inflammatory infiltrate of portal tracts, and bile ductular reaction (Fig. 5.30). It is important to note that biopsies may show histologic features of mechanical obstruction when the initial imaging is negative for obstruction. Furthermore, bile duct obstruction can be a focal process, and therefore histologic features may not be seen in a biopsy from a nonaffected area.
5.5.4 Adverse Drug Reaction
As in nontransplant patients, all forms of drug injury can be seen, including hepatitis and cholestasis. One type of change that is commonly seen in liver allograft is the presence of pseudo–ground-glass hepatocytes (Fig. 5.31) [27]. These deposits closely resemble the ground-glass inclusions of chronic hepatitis B infection. Immunostains for hepatitis B surface antigen may be helpful if there is any clinical concern and serologic testing is not available. Whether the drug injury alone accounts for the allograft dysfunction may not be clear.
5.5.5 Post-transplant Lymphoproliferative Disease (PTLD)
PTLD may present as an atypical portal and/or a lobular infiltration by mononuclear inflammatory cells, or a mass-forming lesion indistinguishable from lymphoma. It is commonly seen in the presence of EBV detected in tissue (Fig. 5.32). See Chap. 9 for more details.
References
Brunt EM. Surgical assessment of significant steatosis in donor livers: the beginning of the end for frozen-section analysis? Liver Transpl. 2013;19:360–1.
Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16:5286–96.
Yersiz H, Lee C, Kaldas FM, Hong JC, Rana A, Schnickel GT, et al. Assessment of hepatic steatosis by transplant surgeon and expert pathologist: a prospective, double-blind evaluation of 201 donor livers. Liver Transpl. 2013;19:437–49.
International Working Party. Terminology for hepatic allograft rejection. Hepatology. 1995;22:648–54.
Liapis H, Wang HL. Pathology of solid organ transplantation. Heidelberg: Springer; 2011. p. xii.
Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25:658–63.
Akamatsu N, Sugawara Y, Tamura S, Keneko J, Matsui Y, Hasegawa K, et al. Late-onset acute rejection after living donor liver transplantation. World J Gastroenterol. 2006;12:6674–7.
Florman S, Schiano T, Kim L, Maman D, Levay A, Gondolesi G, et al. The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transplant. 2004;18:152–5.
Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC, et al. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl. 2008;14:625–32.
Khettry U, Huang WY, Simpson MA, Pomfret EA, Pomposelli JJ, Lewis WD, et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum Pathol. 2007;38:443–52.
Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl. 2008;14:750–5.
Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl. 2008;14:861–71.
Fiel MI, Schiano TD. Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. Curr Opin Organ Transplant. 2012;17:287–92.
Banff Working Group, Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, Czaja A, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006;44:489–501.
Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31:792–9.
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272–83.
Hubscher SG. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant. 2012;17:280–6.
O’Leary JG, Michelle Shiller S, Bellamy C, Nalesnik MA, Kaneku H, Jennings LW, et al. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl. 2014;20:1244–5.
Taner T, Stegall MD, Heimbach JK. Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl. 2014;20:514–27.
Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl. 2007;13:219–26.
Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16:228–35.
Satapathy SK, Sclair S, Fiel MI, Del Rio MJ, Schiano T. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res. 2011;41:328–39.
Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol. 2008;1:396–402.
Lautenschlager I, Halme L, Höckerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis. 2006;8:21–30.
Lefkowitch JH. Bile ductular cholestasis: an ominous histopathologic sign related to sepsis and “cholangitis lenta”. Hum Pathol. 1982;13:19–24.
Lin CC, Sundaram SS, Hart J, Whitington PF. Subacute nonsuppurative cholangitis (cholangitis lenta) in pediatric liver transplant patients. J Pediatr Gastroenterol Nutr. 2007;45:228–33.
Wisell J, Boitnott J, Haas M, Anders RA, Hart J, Lewis JT, Abraham SC, Torbenson M. Glycogen pseudoground glass change in hepatocytes. Am J Surg Pathol. 2006;30:1085–90.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Naini, B.V., French, S.W. (2016). Liver Transplant Pathology. In: Wallace, W., Naini, B. (eds) Practical Atlas of Transplant Pathology. Springer, Cham. https://doi.org/10.1007/978-3-319-23054-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-23054-2_5
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-23053-5
Online ISBN: 978-3-319-23054-2
eBook Packages: MedicineMedicine (R0)